milestones – Talk Bio

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

2 weeks ago talkbio0Tagged annamycin, Clinical Trials, Leukemia, Myelocytic, Acute, milestones, MIRACLE trial, Moleculin, WP1066

Moleculin; MIRACLE trial; Annamycin; WP1066; AML; clinical trials; 2026 milestones

AstraZeneca Pays $100M Upfront, Up to $2B Total for Jacobio’s Pan-KRAS Inhibitor JAB-23E73

1 month ago talkbio0Tagged Antineoplastic Agents, AstraZeneca, Inhibitor, Jacobio Pharma, milestones, pan-KRAS

AstraZeneca; Jacobio Pharma; JAB-23E73; pan-KRAS inhibitor; cancer drug; licensing deal; $100M upfront; $2B milestones

Harbour BioMed inks $90M upfront, $1B+ antibody alliance with Bristol Myers Squibb

1 month ago talkbio0Tagged biobucks, Burning Mouth Syndrome, China, Clinical Trials, global strategic collaboration, Harbour BioMed, Harbour Mice ® technology, Immunology, License Agreement, milestones, multi-specific antibodies, Myers Squibb, Neoplasms

Harbour BioMed; Bristol Myers Squibb; BMS; multi-specific antibodies; $90 million upfront; $1.035 billion milestones; global strategic collaboration; license agreement; Harbour Mice technology; immunology; oncology; biobucks deal; China early clinical trials

Novartis and Relation Therapeutics form AI-driven, multi-program atopic disease collaboration

2 months ago talkbio0Tagged * * atopic diseases * *, * * functional cell, AI-powered, Asthma, atlases, Billion, Drug Discovery, Eczema, Hypersensitivity, IL13 gene, immuno-dermatology, Lab-in-the-Loop, milestones, multi-program collaboration, Novartis

Novartis; Relation Therapeutics; AI-powered drug discovery; Lab-in-the-Loop; atopic diseases; immuno-dermatology; multi-program collaboration; asthma; allergies; eczema; allergic rhinitis; $55 million upfront; $1.7 billion milestones; functional cell atlases

Cereno Scientific Secures SEK 100m in Directed Share Issue and SEK 350m Loan Financing, Targeting Milestones by Q4 2027

2 months ago talkbio0Tagged Cardiovascular Diseases, Cereno Scientific, Clinical Development, Directed share, Histone deacetylase inhibitor, Infrequent, Loan, loan financing, milestones, portfolio, Problem, Pulmonary arterial hypertension

Cereno Scientific; SEK 100 million; Directed share issue; SEK 350 million; Loan financing; Q4 2027 milestones; HDAC inhibitor portfolio; Pulmonary arterial hypertension; Clinical development; Rare cardiovascular diseases

Roche Pays $55M Upfront to Manifold Bio in $2B+ Deal for AI-Guided Next-Gen Brain Shuttles

3 months ago talkbio0Tagged AI drug discovery, BBB, Blood - brain barrier anatomy, Manifold Bio, milestones, Neurological diseases, research, Roche (company), shuttles, therapeutic payloads, upfront payment

Roche; Manifold Bio; blood-brain barrier; BBB shuttles; neurological diseases; AI drug discovery; research deal; upfront payment; milestones; therapeutic payloads

Eli Lilly and Superluminal Ink $1.3B Pact Targeting GPCRs in Obesity, Cardiometabolic Diseases

6 months ago talkbio0Tagged Artificial Intelligence, cardiometabolic diseases, Eli, Eli Lilly, equity, GPCRs, Investments, MC4R, MC4R protein, human, milestones, Obesity, Partnership, Superluminal Medicines

Eli Lilly; Superluminal Medicines; GPCRs; obesity drugs; cardiometabolic diseases; AI drug discovery; MC4R; partnership; milestones; equity investment

BridgeBio Pharma Reports Strong Commercial Progress and Pipeline Updates for 2025

1 year ago talkbio0Tagged 2025, Attruby, BridgeBio Pharma, Clinical Trials, commercial, FORTIFY, Hereditary Diseases, milestones, Phase 3, Propel, status - In progress

BridgeBio Pharma, Attruby, commercial progress, pipeline updates, 2025 milestones, rare genetic diseases, Phase 3 clinical trials, FORTIFY, CALIBRATE, PROPEL 3.